

HALOZYME THERAPEUTICS INC  
Form 4  
December 04, 2007

**FORM 4** UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

OMB APPROVAL  
OMB Number: 3235-0287  
Expires: January 31, 2005  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
Lim Jonathan E

(Last) (First) (Middle)

C/O HALOZYME  
THERAPEUTICS, INC., 11388  
SORRENTO VALLEY ROAD

(Street)

SAN DIEGO, CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol  
HALOZYME THERAPEUTICS  
INC [HALO]

3. Date of Earliest Transaction  
(Month/Day/Year)  
11/30/2007

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer  
  
(Check all applicable)  
 Director  10% Owner  
 Officer (give title below)  Other (specify below)  
President, CEO

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/30/2007		M <sup>(1)</sup>		20,000	A	\$ 0.39
Common Stock	11/30/2007		S <sup>(1)</sup>		2,568	D	\$ 8.31
Common Stock	11/30/2007		S <sup>(1)</sup>		2,132	D	\$ 8.3
Common Stock	11/30/2007		S <sup>(1)</sup>		100	D	\$ 8.29
	11/30/2007		S <sup>(1)</sup>		400	D	
							714,800

Edgar Filing: HALOZYME THERAPEUTICS INC - Form 4

Common Stock					\$ 8.27		
Common Stock	11/30/2007	S <sup>(1)</sup>	300	D	\$ 8.26	714,500	D
Common Stock	11/30/2007	S <sup>(1)</sup>	5,100	D	\$ 8.25	709,400	D
Common Stock	11/30/2007	S <sup>(1)</sup>	1,600	D	\$ 8.23	707,800	D
Common Stock	11/30/2007	S <sup>(1)</sup>	3,360	D	\$ 8.21	704,440	D
Common Stock	11/30/2007	S <sup>(1)</sup>	1,440	D	\$ 8.2	703,000	D
Common Stock	11/30/2007	S <sup>(1)</sup>	298	D	\$ 8.19	702,702	D
Common Stock	11/30/2007	S <sup>(1)</sup>	1,200	D	\$ 8.18	701,502	D
Common Stock	11/30/2007	S <sup>(1)</sup>	602	D	\$ 8.17	700,900	D
Common Stock	11/30/2007	S <sup>(1)</sup>	800	D	\$ 8.16	700,100	D
Common Stock	11/30/2007	S <sup>(1)</sup>	100	D	\$ 8.06	700,000	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)		
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option to Purchase	\$ 0.39	11/30/2007		M <sup>(1)</sup>	20,000	11/11/2003	11/11/2013	Common Stock	20,000

